OncoMatch/Clinical Trials/NCT06496490
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
Is NCT06496490 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including TQB2102 for and TQB2102 for for non-small cell lung cancer.
Treatment: TQB2102 for · TQB2102 for — TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a Phase 2 study to evaluate the efficacy,and safety of TQB2102 for injection in locally advanced or metastatic non-small cell lung cancer with HER2 gene abnormality.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) gene abnormality
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: standard treatments
Previous standard treatments failed
Cannot have received: anticancer therapy or investigational drug
Any anticancer therapy or any other investigational drug treatment within 28 days or 5 half-lives prior to the first dosing of this study
Cannot have received: Chinese patent drugs with anti-tumor indications
Within 1 week prior to the first administration of this study, the Chinese patent drugs with anti-tumor indications clearly stated in the National MedicalProducts Administration approved drug instructions were treated
Cannot have received: local focal palliative radiotherapy
Local focal palliative radiotherapy was received within 2 weeks before the first dose
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06496490 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anticancer therapy or investigational drug, Chinese patent drugs with anti-tumor indications, local focal palliative radiotherapy disqualifies patients from enrollment.
Does this trial require ERBB2?
Yes, ERBB2 gene abnormality is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify